CYAD Stock Price, News & Analysis

Celyad Oncology SA (NASDAQ: CYAD) provided an update on its business and financial results for Q1 2022. The Phase 1 IMMUNICY-1 trial for the allogeneic CAR T candidate CYAD-211 for relapsed/refractory multiple myeloma (MM) is ongoing, with additional data expected in H2 2022. However, the CYAD-101-002 Phase 1b trial remains on clinical hold after two fatalities were reported. As of March 31, 2022, the company had €20.6 million in cash, with a net cash burn of €9.4 million during the quarter, sufficient to fund operations until mid-2023.

Celyad Oncology (CYAD) reported its 2021 results, showing a net loss of €26.5 million or €1.70 per share, a significant increase from €17.2 million or €1.23 per share in 2020. The company had cash and equivalents of €30 million as of Dec 31, 2021, expected to fund operations until mid-2023. Clinical updates included encouraging results from the Phase 1 IMMUNICY-1 trial of CYAD-211 for relapsed/refractory multiple myeloma, while the CYAD-101 Phase 1b trial is on clinical hold. The firm anticipates upcoming data releases and IND submissions in 2022.

Celyad Oncology (Euronext & Nasdaq: CYAD) announced it will report its full year 2021 financial and operational results on March 24. Following the results, management will host a conference call on March 25 at 1 p.m. CET to discuss the outcomes and provide updates on recent progress and milestones. Celyad specializes in the development of CAR T cell therapies for cancer treatment, focusing on both allogeneic and autologous therapies to address various malignancies.

Celyad Oncology SA (Euronext & Nasdaq: CYAD) announced that the U.S. FDA placed a clinical hold on its CYAD-101-002 (KEYNOTE-B79) Phase 1b trial on March 1, 2022, due to insufficient risk assessment data. This decision follows the company's voluntary pause of the trial on February 28, 2022, after reports of two fatalities. Celyad specializes in CAR T cell therapies for cancer treatment, focusing on both allogeneic and autologous candidates.

Celyad Oncology SA (CYAD) has announced a voluntary pause of the CYAD-101-002 (KEYNOTE-B79) Phase 1b trial due to reports of two fatalities with similar pulmonary issues. This trial investigates the CYAD-101 therapy, designed for patients with refractory metastatic colorectal cancer. The company prioritizes patient safety and is investigating these serious incidents while keeping regulatory bodies informed. Previous trials with CYAD-101 showed no dose-limiting toxicities. Celyad anticipates no impact on its other candidates, including CYAD-211 for multiple myeloma.

Celyad Oncology announced its participation in the 11th Annual SVB Leerink Global Healthcare Conference from February 14 to 18, 2022, with a presentation scheduled for February 18 at 8 a.m. ET by CEO Filippo Petti. The company focuses on developing chimeric antigen receptor T cell (CAR T) therapies for cancer, including both allogeneic and autologous treatments for hematological malignancies and solid tumors. Celyad has received funding from the Walloon Region of Belgium to support its CAR T programs.

Celyad Oncology (CYAD) announces promising advancements in its allogeneic CAR T therapies, highlighting 2021's achievements and 2022 goals. The company aims to deliver key data from the KEYNOTE-B79 and IMMUNICY-1 clinical trials for CYAD-101 and CYAD-211 as they progress. The proprietary shRNA technology has been validated, offering a competitive edge, while a recent $32.5 million investment from Fortress Investment Group strengthens its financial position. Celyad ended 2021 with a treasury of €30 million ($34 million), ensuring funding into mid-2023.

Celyad Oncology SA announced a capital increase on 8 December 2021, issuing 6,500,000 new shares to Fortress Investment Group. This raised the total share capital to 78,584,224.33 EUR and resulted in a total of 22,593,956 shares, comprising 20,225,931 with single voting rights and 2,368,025 with double voting rights. The adjusted total diluted shares stand at 24,591,146, enhancing the voting rights to 26,959,171. This move complies with Belgian regulations on major shareholdings disclosures.